1. Academic Validation
  2. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies

First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies

  • J Med Chem. 2015 Feb 26;58(4):1644-68. doi: 10.1021/jm500672y.
Céline Gloaguen 1 Anne Sophie Voisin-Chiret Jana Sopkova-de Oliveira Santos Jade Fogha Fabien Gautier Marcella De Giorgi Grégory Burzicki Serge Perato Cécile Pétigny-Lechartier Karin Simonin-Le Jeune Emilie Brotin Didier Goux Monique N'Diaye Bernard Lambert Marie-Hélène Louis Laetitia Ligat Frédéric Lopez Philippe Juin Ronan Bureau Sylvain Rault Laurent Poulain
Affiliations

Affiliation

  • 1 Normandie Université , 14032 Caen, France.
Abstract

Apoptosis control defects such as the deregulation of Bcl-2 Family member expression are frequently involved in chemoresistance. In ovarian carcinoma, we previously demonstrated that Bcl-xL and Mcl-1 cooperate to protect Cancer cells against Apoptosis and their concomitant inhibition leads to massive Apoptosis even in the absence of chemotherapy. Whereas Bcl-xL inhibitors are now available, Mcl-1 inhibition, required to sensitize cells to Bcl-xL-targeting strategies, remains problematic. In this context, we designed and synthesized oligopyridines potentially targeting the Mcl-1 hydrophobic pocket, evaluated their capacity to inhibit Mcl-1 in live cells, and implemented a functional screening assay to evaluate their ability to sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. We established structure-activity relationships and focused our attention on MR29072, named Pyridoclax. Surface plasmon resonance assay demonstrated that pyridoclax directly binds to Mcl-1. Without cytotoxic activity when administered as a single agent, pyridoclax induced Apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma Cancer cells.

Figures
Products